Petrelintide official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
ZUPREME 1 excludes diabetes
NCT06662539 records 493 participants in a placebo-controlled phase 2 study of overweight or obesity. The eligibility criteria exclude diabetes and diabetic-range HbA1c, defining a different population from the diabetes program. NCT06662539 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
ZUPREME 2 includes specified background diabetes treatment
NCT06926842 records 221 participants with type 2 diabetes treated with stable metformin, with or without an SGLT2 inhibitor. That background matters when interpreting glycemic or safety findings eventually reported. NCT06926842 ↗
Both primary endpoints concern weight at 28 weeks
Both records specify percentage body-weight change through week 28. This endpoint does not directly measure cardiovascular events, sustained benefit after stopping treatment, or every obesity-related complication. NCT06662539 ↗NCT06926842 ↗
The status updates are not efficacy results
Both retrieved records are marked completed, but neither includes posted summary results. ZUPREME 2 was last updated on September 9, 2026. Any effect estimate needs a separate results source rather than being inferred from completion. NCT06662539 ↗NCT06926842 ↗
What remains to be checked
- Match ZUPREME publications or subsequent registry results to each protocol before adding effect estimates.
- Review durability, discontinuation, gastrointestinal events and other safety findings in the diabetes and non-diabetes populations separately.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities ↗
Source dated 2026-03-23; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.eligibilityModule and armsInterventionsModule
- protocolSection.outcomesModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
a2d36b0b87f5de73bac31586f05407a69f07b01021771b76fc63cd04020bf763Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) ↗
Source dated 2026-09-09; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.eligibilityModule and armsInterventionsModule
- protocolSection.outcomesModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
12627b63a37b7c06a1d1772d78953ac7aef94b809c2be4b848f05d407fa796a3